London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
You will only have one login account. Registering with multiple accounts is not allowed. Any user found to have more than one account on this site will have all, and any future accounts suspended permanently.
Your email and password must only be used by you. If a post is made under your account, it will be considered that it was posted by yourself.
Your account nickname must not be the same, or contain, listed company names or board members' names.
While debating and discussion is fine, we will not tolerate; rudeness, swearing, insulting posts, personal attacks, or posts which are invasive of another's privacy.
You will not;
discuss illegal or criminal activities.
post any confidential or price sensitive information or that is not public knowledge.
post misleading or false statements regarding the share price and performance. Such posts are deemed as market abuse, and may be reported to the appropriate authorities.
post any private communication, or part thereof, from any other person, including from a member of the board of directors of a listed company. Such posts cannot be verified as true and could be deemed to be misleading.
post any personal details (e.g. email address or phone number).
post live price or level 2 updates.
publish content that is not your original work, or infringes the copyright or other rights of any third party.
post non-constructive, meaningless, one word (or short) non-sense posts.
post links to, or otherwise publish any content containing any form of advertising, promotion for goods and services, spam, or other unsolicited communication.
post any affiliate or referral links, or post anything asking for a referral.
post or otherwise publish any content unrelated to the board or the board's topic.
re-post premium share chat posts on regular share chat.
restrict or inhibit any other user from using the boards.
impersonate any person or entity, including any of our employees or representatives.
post or transmit any content that contains software viruses, files or code designed to interrupt, destroy or limit the functionality of this website or any computer software or equipment.
If you are going to post non-English, please also post an English translation of your post.
If you are going to post non-English, please also post an English translation of your post.
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium and Verified Members
Premium Members are members that have a premium subscription with London South East and have access to Premium Chat. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Hi Roses, (Hasiba, RW etc.). With respect I think there's more than 'a hope in hell' and the post is very likely to be genuine. IF it was false, surely Vulpes or Prof. Peter James will before too long, surely do something to refute it.
If you remember, the appearance of NXC was greeted with stubborn doubt for weeks/months by some - on the other hand, many of us seemed to know instinctively it was indeed DE.
IMO this piece, kindly found by 'Chillpill', who has proved to be a helpful Poster before, is very likely to be genuine. As in the NXC matter, the way it is written suggests the highest level of understanding and a professional way of putting the case.
IF this piece had been put together by some clever ramper, he would have neede to pull a script with that level of expertise, from somewhere else, and I note our bloodhounds here and there, have not yet 'found' what might be the 'real' source, yet.
It looks to me that it might be a Vulpes script used for their own purposes, with other Investors ?
Whilst I could be wrong, I think it IS genuine. GLA
Indeed miavoce. Further digging and googling brings up this older post from the 'other side' - 21/8/2019 15:54gooosed: Berm - yes, sorry didn't explain very well. Diggle's man in Sweden, Prof. Peter James (PhD BioChem Oxford & Prof. of BioChem & Proteomics @ Lunde University in Sweden) saw enough to have Diggle stump up £4m. While the rest of the Bio/Pharma world pass Scancell by (seems to include BioNTech now too) - pure speculation on my part but perhaps there are links/connections via Karolinska Institutet.
Not criticising miavoce here, i can see chillpill on A D V F N posted it, question is, where did he get it from? Hopefully it is genuine, but...even as fully paid up member of team ramp, blatant and possibly false ramping needs to be avoided as much as de-ramping/making stuff up to talk a share down. They are as bad as each other IMO.
P.s. Nothing seems to come back if you google the first line "There has been significant excitement in both the media and the scientific community over the new approach from Scancell on targeting the Covid virus"
No link because it’s written by amateur Ramper ....or a journalist but not by a professor or Vulpes.. Sleep well guys... Please find the link to help me change my mind...asap! The contents ok and known to us though...but GN
Posted by chillpill on the other site. If this view from Vulpes is based on their knowledge of the current state of progress in Scancell then this is hope mews indeed.
The Vulpes view:
There has been significant excitement in both the media and the scientific community over the new approach from Scancell on targeting the Covid virus. The stock has performed spectacularly well in the last few months and we wanted to go into some depth as to the possible advantages of the Scancell approach, as these could deliver significant returns for our investors. Professor Peter James writes, “Currently, virtually all of the vaccines developed to date target a protein on the outside of the viral capsid called the Spike protein (S). The function of this protein is to bind a receptor on the outside of cells (called ACE2) this then causes the virus to be taken into the cell. Once inside, the virus can use the cell's machinery to replicate and subsequently kill the cell allowing the release of thousands of new virus particles. The Spike protein is the most easily accessible for immune cells to see and bind to, and to allow the virus to be killed. However, it is fairly easily mutated since its function is simply to bind the receptor and so does not have such a critical reliance on overall structure. This flexibility is now a cause for worry since by changing its sequence it may be able to avoid detection by the immune cells that were elicited by the current vaccines. Scancell’s strategy is to target this S protein and a second protein inside the viral membrane called the nucleocapsid protein, N. This protein is responsible for a series of critical steps in the viral lifecycle including packaging the viral genome, directing assembly of the virus and eliciting viral escape from the cell by budding. Since it has many functions, its structure is very fixed and it cannot mutate very much without losing function and killing the virus. This protein is found in many Coronaviruses and the sequence is pretty much invariant. By targeting two proteins, the chances of resistance to vaccination by mutation is dramatically reduced and should provide protection against future mutations. Also, it has the added benefit of probably being effective against other Coronaviruses. The intention is to induce both durable T cell responses and virus neutralising antibodies to give a more potent and longer lasting response that is likely to be able to deal with new mutations arising in the future.” Vulpes originally invested in Scancell for the brilliant cancer immunology, however it appears increasingly possible that their Covid vaccine, named Covidity, may produce another significant pillar of value of our investors. Even better is that such is the enthusiasm for the project the UK government has given he company an Innovate UK grant to cover most of much of the development. Human trials are due to start in the coming weeks and we should have early results by the beginning of
And I think yesterday presentation has saved our day! Can you imagine if the market didn’t like it in a day like this...we would have been probably around the 15 p marks... Half of the earlier losses recovered.....I like that and looking forward to the next week more recovery.... Have a good weekend